SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health ($OSCR) is trending after the House passed a bill to extend ACA subsidies, sparking intense community debate on its potential for future growth and profitability, with investors keenly focused on the upcoming earnings report and crucial 2026 guidance amidst broader healthcare sector sentiment.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending following strong Q4 earnings and a new share buyback, prompting community debate over its significant stock-based compensation and dilutive practices, particularly as reports circulate about Meta's Instagram developing a rival app.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv (FISV) is actively trending as investors keenly await its earnings report, fueling intense community debate between those who believe the stock is deeply undervalued with a promising turnaround under new leadership, and others bracing for a significant drop mirroring previous disappointments and broader fintech sector headwinds. Significant options activity indicates widespread expectation of a volatile price movement following the announcement.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending due to the FDA's Complete Response Letter for its Hunter syndrome gene therapy, RGX-121, citing concerns over trial design, including natural history controls and the surrogate endpoint. This decision has ignited community debate, with many investors anticipating a substantial stock drop and others expressing frustration over the FDA's stringent approach to rare disease gene therapies.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork (UPWK) is trending sharply lower after providing a weaker-than-expected outlook, despite reporting a beat on its recent earnings. The community is actively debating if the platform is becoming obsolete due to advancing AI technology, while some view the sell-off as an overreaction and a buying opportunity.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc. is trending after the abrupt departures of its CFO and General Counsel amid an ongoing accounting review, an SEC investigation, and disclosures of material weaknesses in internal controls and a lowered fiscal outlook. The community is sharply divided, with many voicing deep concerns about potential fraud and a continued decline, while others are aggressively buying the significant dip, anticipating an oversold rebound.

Dynatrace, Inc. engages in the advancing observability for today’s digital businesses, helping to transform the complexity of modern digital ecosystems into powerful business assets. By leveraging AI-powered insights, Dynatrace enables organizations to analyze, automate, and innovate faster to drive their business forward. The company was founded by Bernd Greifeneder in 2005 and is headquartered in Boston, MA.

Dynatrace Inc

Dynatrace is trending following a strong earnings report for Q3 fiscal year 2026, which surpassed expectations across key metrics, alongside the authorization of a $1 billion share repurchase program, sparking community discussion about a potential turnaround.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending amid a broad software sector sell-off, fueled by investor concerns that rapidly advancing AI will disrupt or replace traditional SaaS models. While some analysts and market participants argue that AI will enhance core enterprise software and point to a significant government contract, the community remains polarized between those calling it a "generational buying opportunity" and those fearing further valuation compression.

Investment Managers Series Trust II - Tradr 2X Long CRML Daily ETF

Tradr 2X Long CRML Daily ETF

The Tradr 2X Long CRML Daily ETF ($CRMX) is actively trending following its recent launch, offering leveraged exposure to Critical Metals ($CRML) and its rare earth projects, with the community highly engaged in debate over its volatile performance and potential for significant moves.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is trending following strong Q4 2025 financial results and positive FY26 guidance, bolstered by recent FDA approvals for its oncology blockbusters Enhertu and Datroway, and groundbreaking Phase 3 data for hypertension treatment Baxdrostat. The community is actively discussing the company's strategic direct listing on the NYSE, along with significant investments in US manufacturing and an expanding obesity pipeline in China, all signaling a robust long-term growth outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Inhibikase Therapeutics (NYSE:IKT) Earns Buy Rating from Analysts at Bank of America

Bank of America initiated coverage on shares of Inhibikase Therapeutics in a research report on Wednesday. They set a "buy" rating and a $6.00 price target on the stock...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) have been assigned a consensus rating of "Buy" from the five analysts that are presently covering the firm, Marketbeat reports...

Inhibikase Therapeutics (NYSE:IKT) Trading Up 1.2% - What's Next?

Inhibikase Therapeutics (NYSE:IKT) Shares Up 1.2% - What's Next...

Short Interest in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Rises By 29.0%

Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totaling...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Brokerages

Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has earned a consensus recommendation of "Buy" from the five analysts that are presently covering the company, MarketBeat reports. One...

Inhibikase Therapeutics (NASDAQ:IKT) Raised to "Strong-Buy" at HC Wainwright

HC Wainwright raised shares of Inhibikase Therapeutics to a "strong-buy" rating in a research report on Friday...

Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Sell at Wall Street Zen

Wall Street Zen raised Inhibikase Therapeutics to a "sell" rating in a report on Saturday...

Inhibikase Therapeutics (NYSE:IKT) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective on shares of Inhibikase Therapeutics in a research note on Friday...

Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Strong-Buy at Cantor Fitzgerald

Cantor Fitzgerald raised shares of Inhibikase Therapeutics to a "strong-buy" rating in a research note on Thursday...

Cantor Fitzgerald Initiates Coverage on Inhibikase Therapeutics (NYSE:IKT)

Cantor Fitzgerald initiated coverage on Inhibikase Therapeutics in a report on Thursday. They issued an "overweight" rating and a $4.00 price target on the stock...

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Wilmington, DE.

Inhibikase Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

IKT
Inhibikase Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IKT News

IKTInhibikase Therapeutics Inc